Multiple myeloma is an incurable plasma cell malignancy despite major therapeutic advances. A recent review by Chinese researchers highlights how immunotherapy is reshaping its treatment landscape. The article summarizes immune mechanisms driving disease progression and explores emerging targets, such as BCMA, GPRC5D, and FcRL5. It also presents promising approaches—antibody–drug conjugates, CAR-T cells, and bispecific antibodies—offering new opportunities for overcoming drug resistance and achieving durable, personalized cancer immunotherapy.

The 2024 report on China’s gastroenterology and digestive endoscopy, based on national databases, highlights increased early cancer detection, optimized care for priority diseases, and enhanced endoscopy quality, with mixed cost trends for inflammatory bowel disease.